Halal Stock Search
Unlockmore than 90 stock exchanges for FREE
{{companyExchange}}
Company Name |
Company Symbol |
Exchange |
Pfizer |
PFE |
NYSE |
Warning: The result may change based on other methodologies. As of the recent update on Wednesday 17th of July 2024 , is considered as Halal based on FTSE methodology. To access full report and unlock the detailed results with associated ratios for 5 halal investment methodologies, you can click below.
Main Activity |
Activity test result |
Pharmaceuticals |
PASS |
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Total Debt |
Interest free debt |
Adjusted debt level |
Total Asset |
Debt Ratio |
PASS or FAIL |
64310166400 |
0 |
64310166400 |
215021000000 |
29.91% |
PASS |
Cash |
Cash Eq. |
Short Term Investment |
Total Asset |
Cash & Eq. ratio |
PASS or FAIL |
0 |
3148000000 |
41033000000 |
215021000000 |
20.55% |
PASS |
Cash |
Cash Eq. |
Net Accounts Receivables |
Total Asset |
Quick ratio |
PASS or FAIL |
0 |
3148000000 |
11086000000 |
215021000000 |
6.62% |
PASS |
Net Interest Income (Expense) as non-Operating
Total Non permissible and doubtful income |
Total revenue |
Non permissible and doubtful income ratio |
PASS or FAIL |
0 |
14878000000 |
0% |
PASS |